# EDGAR Filing Document

**Accession Number:** 0001808865
**File Stem:** 0001214659-25-009148
**Filing Date:** 2025-6
**Character Count:** 25116
**Document Hash:** 195b25e70399547baf5437c00ee54819
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-25-009148.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001214659-25-009148

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iTeos Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001808865
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91596
- **FILM NUMBER:** 251043124

**BUSINESS ADDRESS:**
- **STREET 1:** 321 ARSENAL STREET
- **STREET 2:** BLDG 312, FLOOR 3, SUITE 301
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 857-204-4583

**MAIL ADDRESS:**
- **STREET 1:** 321 ARSENAL STREET
- **STREET 2:** BLDG 312, FLOOR 3, SUITE 301
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TANG CAPITAL MANAGEMENT LLC
- **CENTRAL INDEX KEY:** 0001232621

**ORGANIZATION NAME:**
- **EIN:** 461592449
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 4747 EXECUTIVE DRIVE
- **STREET 2:** SUITE 210
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-200-3830

**MAIL ADDRESS:**
- **STREET 1:** 4747 EXECUTIVE DRIVE
- **STREET 2:** SUITE 210
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

## Exhibit 99.1

**EXHIBIT 1**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, par value $0.001 per share, of ITeos Therapeutics, Inc., and that this Agreement be included as an Exhibit to such joint filing. The Agreement may be executed in any number of counterparts all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Agreement this 12<sup>th</sup> day of June, 2025.

---

| | |
|:---|:---|
| TANG CAPITAL MANAGEMENT, LLC | TANG CAPITAL MANAGEMENT, LLC |
| By: | /s/ Kevin Tang |
|  | Kevin Tang, Manager |

---

---

| |
|:---|
| /s/ Kevin Tang |
| Kevin Tang |

---

---

| | |
|:---|:---|
| TANG CAPITAL PARTNERS, LP | TANG CAPITAL PARTNERS, LP |
| By: Tang Capital Management, LLC, its General Partner | By: Tang Capital Management, LLC, its General Partner |
| By: | /s/ Kevin Tang |
|  | Kevin Tang, Manager |

---

---

| | |
|:---|:---|
| TANG CAPITAL PARTNERS INTERNATIONAL, LP | TANG CAPITAL PARTNERS INTERNATIONAL, LP |
| By: Tang Capital Management, LLC, its General Partner | By: Tang Capital Management, LLC, its General Partner |
| By: | /s/ Kevin Tang |
|  | Kevin Tang, Manager |

---

---

| | |
|:---|:---|
| TANG CAPITAL PARTNERS III, INC | TANG CAPITAL PARTNERS III, INC |
| By: | /s/ Kevin Tang |
|  | Kevin Tang, Chief Executive Officer |

---

---

| | |
|:---|:---|
| TANG CAPITAL PARTNERS IV, INC | TANG CAPITAL PARTNERS IV, INC |
| By: | /s/ Kevin Tang |
|  | Kevin Tang, Chief Executive Officer |

---

---

| | |
|:---|:---|
| CONCENTRA BIOSCIENCES, LLC | CONCENTRA BIOSCIENCES, LLC |
| By: | /s/ Kevin Tang |
|  | Kevin Tang, Chief Executive Officer |

---

## Exhibit 99.2

**EXHIBIT 2**

**Schedule A**

**Transactions during the past 60 days**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Transaction Date** | **Nature of <br> Transaction** | **Quantity** | **Weighted Average <br> Price Per Share\*** | **Price Range** | **Price Range** |
| **Transaction Date** | **Nature of <br> Transaction** | **Quantity** | **Weighted Average <br> Price Per Share\*** | **Min** | **Max** |
| 4/23/2025 | Sale | 58742 | $7.24 | $7.05 | $7.60 |
| 4/24/2025 | Sale | 23439 | $7.25 | $7.01 | $7.46 |
| 4/25/2025 | Sale | 32497 | $7.35 | $7.23 | $7.50 |
| 4/28/2025 | Sale | 31731 | $7.22 | $7.02 | $7.36 |
| 4/28/2025 | Sale | 156 | $7.16 | $7.14 | $7.20 |
| 4/29/2025 | Sale | 4349 | $7.17 | $7.03 | $7.33 |
| 4/30/2025 | Sale | 49086 | $7.17 | $7.00 | $7.25 |
| 5/13/2025 | Purchase | 1000000 | $8.18 | $7.50 | $8.50 |
| 5/13/2025 | Purchase | 189492 | $7.92 | $7.78 | $8.04 |
| 5/13/2025 | Purchase | 416 | $8.02 | $7.89 | $8.10 |
| 5/14/2025 | Purchase | 10092 | $7.96 | $7.87 | $8.12 |
| 5/14/2025 | Purchase | 100000 | $7.43 | $7.33 | $7.55 |

---

*\*The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased or sold at each price within the ranges set forth in the table above.*

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**ITeos Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**46565G104**

*(CUSIP Number)*

**Kevin Tang**<br>4747 Executive Drive<br>Suite 210<br>San Diego CA 92121<br>858-200-3830

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/11/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **46565G104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**TANG CAPITAL MANAGEMENT, LLC** | Name of reporting person<br>**TANG CAPITAL MANAGEMENT, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3826692.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3826692.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3826692.00** | Aggregate amount beneficially owned by each reporting person<br>**3826692.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.99%** | Percent of class represented by amount in Row (11)<br>**9.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Tang Capital Management, LLC ("TCM") shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI") and Kevin Tang. The percentages used herein are based on 38,273,795 shares of Common Stock outstanding as of April 22, 2025, as set forth in the Issuer's Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on April 28, 2025.

| **CUSIP No.** | **46565G104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**KEVIN TANG** | Name of reporting person<br>**KEVIN TANG** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3826692.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3826692.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3826692.00** | Aggregate amount beneficially owned by each reporting person<br>**3826692.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.99%** | Percent of class represented by amount in Row (11)<br>**9.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI and TCM.

| **CUSIP No.** | **46565G104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**TANG CAPITAL PARTNERS, LP** | Name of reporting person<br>**TANG CAPITAL PARTNERS, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2618219.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2618219.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2618219.00** | Aggregate amount beneficially owned by each reporting person<br>**2618219.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.84%** | Percent of class represented by amount in Row (11)<br>**6.84%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** TCP shares voting and dispositive power over such shares with TCM and Kevin Tang.

| **CUSIP No.** | **46565G104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**TANG CAPITAL PARTNERS INTERNATIONAL, LP** | Name of reporting person<br>**TANG CAPITAL PARTNERS INTERNATIONAL, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1208473.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1208473.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1208473.00** | Aggregate amount beneficially owned by each reporting person<br>**1208473.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.15%** | Percent of class represented by amount in Row (11)<br>**3.15%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang.

| **CUSIP No.** | **46565G104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**TANG CAPITAL PARTNERS III, INC** | Name of reporting person<br>**TANG CAPITAL PARTNERS III, INC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**NEVADA** | Citizenship or place of organization<br>**NEVADA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **46565G104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**TANG CAPITAL PARTNERS IV, INC** | Name of reporting person<br>**TANG CAPITAL PARTNERS IV, INC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**NEVADA** | Citizenship or place of organization<br>**NEVADA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **46565G104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**CONCENTRA BIOSCIENCES, LLC** | Name of reporting person<br>**CONCENTRA BIOSCIENCES, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
ITeos Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
321 Arsenal Street, Bldg 312, Floor 3, Suite 301, Watertown, MA, 02472

**Item 4. Purpose of Transaction**

The Reporting Persons are filing this Statement as an amendment to their Schedule 13G previously filed on May 15, 2025. The Reporting Persons purchased the Common Stock reported hereunder for investment purposes, and such purchases were made in the Reporting Persons' ordinary course of business.

As with their other investments, the Reporting Persons continuously evaluate the Issuer, including, but not limited to, its businesses, operations and prospects. The Reporting Persons may engage in discussions with the Issuer and its representatives and/or other stockholders and/or discuss with the Issuer different strategic alternatives or changes to the Issuer's operations. There can be no certainty as to whether discussions with the Issuer will occur, the outcome of any such discussions or whether the Reporting Persons will take any actions relating to the Issuer.

Subject to applicable law and regulation, the Reporting Persons may modify their ownership of the Common Stock, including acquiring additional Common Stock or disposing of some or all of the Common Stock beneficially owned by them. Such actions may be based on the Reporting Persons' assessment of the Issuer's operations and prospects, prevailing market conditions or other investment considerations.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons beneficially own an aggregate of 3,826,692 shares of the Issuer's Common Stock, representing 9.99% of the outstanding shares.

**(b)**
See item 5(a) above.

**(c)**
Schedule A attached hereto as Exhibit 2 describes all transactions in the Issuer's Common Stock that were effected during the past 60 days by the Reporting Persons.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

To the best of the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between the Reporting Persons and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** TANG CAPITAL MANAGEMENT, LLC

**Signature:** /s/ Kevin Tang

**Name/Title:** Manager

**Date:** 06/12/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** KEVIN TANG

**Signature:** /s/ Kevin Tang

**Name/Title:** Self

**Date:** 06/12/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** TANG CAPITAL PARTNERS, LP

**Signature:** /s/ Kevin Tang

**Name/Title:** Manager, Tang Capital Management, LLC, General Partner

**Date:** 06/12/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** TANG CAPITAL PARTNERS INTERNATIONAL, LP

**Signature:** /s/ Kevin Tang

**Name/Title:** Manager, Tang Capital Management, LLC, General Partner

**Date:** 06/12/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** TANG CAPITAL PARTNERS III, INC

**Signature:** /s/ Kevin Tang

**Name/Title:** Chief Executive Officer

**Date:** 06/12/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** TANG CAPITAL PARTNERS IV, INC

**Signature:** /s/ Kevin Tang

**Name/Title:** Chief Executive Officer

**Date:** 06/12/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** CONCENTRA BIOSCIENCES, LLC

**Signature:** /s/ Kevin Tang

**Name/Title:** Chief Executive Officer

**Date:** 06/12/2025